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Abstract
HCV is prevailed in the world as well as in China. Blood transfusion is one of the most common transmission path-
ways of this pathogen. Although data of HCV infection character were reported during the past years, anti-HCV
reactive profile of China donors was not fully clear yet. Furthermore, infection progress was found related to the
HCV genotype. Different genotype led to different efficacy when interferon was introduced into HCV therapy. Here
we provided character data of HCV infection in China blood donors from the year of 2000 to 2009. The infection
rate in local donors was lower than general population and descended from 0.80% to 0.40% or so in recent years.
About 83% HCV strains were categorized into genotypes 1b and 2a. But 1b subtype cases climbed and 2a subtype
cases decreased. The current study threw more light on HCV infection of blood donors in China, at least in the
Northern region.
Background
H e p a t i t i sCv i r u s( H C V )i n f e c t i o nr a t ei sa b o u t3 %a n d
more than 170 million people are currently infected by
HCV in the world [1]. More than 3.5 million new suf-
ferers annually occurred [2]. The situation is more ser-
ious in China because more than 50 million HCV cases
located in this country [3]. This infection, mainly trans-
mitted by blood transfusion in China, could progress to
cirrhosis liver and hepatocarcinoma [4].
HCV is an enveloped virus with a single strand posi-
tive and non- fragment RNA. The genome of HCV is
about 9 400 nucleotides, which encodes approximately 3
000 amino acids [5]. The high heterogenic nucleotides
of HCV were confirmed and at least six different geno-
types have generally been divided [6,7]. Furthermore,
HCV quasispecies were clarified also according to more
detailed HCV genome variation [8-10].
The distribution of HCV genotypes and subtypes
depends on geographical location and race deference
[2,7,8,11]. Type 1a, the first identified sequence, was
popular in the United States, while Asia cases were
observed also. About 10-30% HCV infection belonged to
type 2a and 2b virus in the world. Type 2a and 2b
pathogens prevailed in the North America, Europe,
China and Japan. Type 2c strains occurred only in the
North region of Italy. Type 3 viruses were more
observed in India, Southeast Asia and Indonesia. But
type 3a strain prevailed in drug users in the North Eur-
ope and United States and mixed with type 1a virus
infection. Type 4 virus was mainly reported in the Medi-
terranean Sea country. More than 39.2% cases belonged
to type 5 family in the South Africa. Type 6 virus infec-
tions concentrated in the Southwest of China, including
Hong Kong and Taiwan region.
It is significant to discern HCV genotype because infec-
tion progress was found related to the nuclei acid
sequence variation [12,13]. Different genotype led to dif-
ferent efficacy when interferon was introduced into HCV
therapy [14]. Actually, HCV genotypes were regarded as
an independent prediction factor in interferon
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necessary in clinic, including transfusion medicine.
Although HCV genotyping was once performed in
China, the infection character and genotype distribution
is not fully clear yet in blood donors [16-18]. Since gene
sequence variation may lea possible failure in donor’s
screen test, it is imperative to obtain epidemiological
data to decrease the blood transmission risk.
The aim of this study was to analyze the HCV epide-
miology in local donor population in the past 10 years.
The distribution and formulation of HCV infection was
also clarified here. HCV genotypes of local blood donors
were probed in the current study.
Results
Infection rate in the last 10 years decreased
To determinate the HCV infection rate in local blood
donors, ELISA was performed according to the standard
donor peripheral blood test procedure. From the January
of 2000 to the December of 2009, about 0.45% (1151/
273203) blood donors were found with anti-HCV posi-
tive reaction. As shown in Fig. 1, the infection rate is
higher in the early of the study period. In the year of
2001, 0.81% donors were anti-HCV reactive. From the
year of 2004, anti-HCV reactive rate in donors
decreased to 0.42% and kept stable in the followed
years. In the year of 2010, HCV infection rate is 0.54%
hitherto (117/21578, up to 31
st May, 2010).Those data
implied that anti-HCV reactive donors decreased in the
latest 5 years in local region.
Most of the anti-HCV reactive donors were low-grade
infection
The relative value of sample absorbance and cutoff (S/
CO) can somewhat reflect the degree of HCV infection.
Thus we divided the 1151 anti-HCV reactive donors
into different groups (Fig. 2A, black). More than 50%
anti-HCV reactive donors’ S/CO values were fewer than
2.0, while about 45% anti-HCV reactive donors’ S/CO
values were between 2.1 and 4.0. In ALT level measure-
ment, more than 80% anti-HCV reactive donors’ value
was between 40 IU/L and 120 IU/L (Fig. 2B, black),
while only a few donors’ value was lower than 40 IU/L
or higher than 120 IU/L. The 200 recruited donors for
genotyping displayed similar distribution character (Fig.
2A and 2B, blank), which meant that the chosen sample
pool, at least in part, could represent the total HCV
infected donors in the current study. When HCV viral
load detection was performed in the 200 recruited
donors, about 61% samples’ viral load were between 1 ×
10
2 and 1 × 10
3 copies/ml, while 16.3% samples’ viral
load fell into 1 × 10
4 copies/ml (Fig. 2C). Altogether,
these results suggested that most of the local anti-HCV
reactive donors, without syndromes, had a low-grade
infection when their blood collected.
Genotypes distribution and changes in local region
To explore the HCV genotypes of local donors in the
past 10 years, we chose 20 samples each year to perform
genotyping. As shown in Table 1, 135 (67.5%) donors
were 1b infection and 31 donors (15.5%) were 2a infec-
tion. The donor’s age or sex was not associated with
HCV infection. To be noted, 2 donors were mixed infec-
tion (1b and 2a) and 3 donors’ infection genotype was
not clarified. Furthermore, we compared 1b and 2a sub-
types infection between donors and clinic confirmed
patients. Results showed that 1b and 2a subtypes infec-
tion was no difference in these two groups (Fig. 3A).
These data indicated that most of the local anti-HCV
reactive donors infected with 1b and 2a subtypes virus.
Since 1b and 2a HCV virus were the prevailed strains
in local infected donors, we are wondering whether the
Figure 1 HCV infection rate in blood donors from the year of 2000 to 2009. Donors’ peripheral blood serum were isolated and employed
to ELISA to test reactive anti-HCV antibody. Bars represent the 95% confidence interval.
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shown in Fig. 3, the cases of 1b genotypes decreased in
local HCV infected donors, from 16 cases in the year of
2000 to 11 cases in the year of 2009 (Fig. 3B), while the
cases of 2a genotypes increased in the last 10 years(Fig.
3C). Other genotypes did not change (data not shown).
These results showed that in the past 10 years, the two
main genotypes (1b and 2a) in local HCV infected
donors underwent a switch, although not so markedly.
ALT and viral load in follow up research
To monitor HCV infection progress after the prelimin-
ary analysis, we tracked some reactive donors, who
donated blood from the year of 2000 to the year of 2007
and were genotyped also as mentioned above, in the fol-
lowing 2 years. These samples were negative also for
other hepatitis virus. Consecutive ALT testing showed
that the liver function of these donors infected with
HCV, at least partly, impaired one year later or so after
donation (Table 2). Especially, 1b genotype virus
infected donors had a higher ALT level than that of
Figure 2 HCV reactive profile of blood donors in represented (blank) and total samples (black). Represented and total samples from
donors were administrated to standard ELISA, ALT and real-time PCR determination methods. The map was drawn according to different range
respectively. A, S/CO value distribution of donors in anti-HCV antibody test; B, ALT value distribution of donors; C, viral load distribution of
represented donors. E1:1 × 10
1; E2:1 × 10
2; E3:1 × 10
3; E4:1 × 10
4; E5:1 × 10
5.
Table 1 Genotype distribution in anti-HCV reactive
donors from 200 represented samples
Genotype Cases Percentage (%) Sex Ratio Mean Age
1a 10 5.0 2.1 41 ± 10.1
1b 135 67.5 1.1 39 ± 11.6
2a 31 15.5 1.3 38 ± 8.9
2b 6 3.0 0.4 45 ± 12.3
3a 5 2.5 0.2 33 ± 11.4
3b 5 2.5 1.1 43 ± 7.1
6a 3 1.5 0.3 45 ± 14.3
1b+2a 2 1.0 0.8 34 ± 11.3
NC 3 1.5 0.7 29 ± 8.7
Total 200 100 0.9* 36 ± 9.7**
Sex Ratio was counted on the Number of males to that of females.
NC: Not clarified genotype.
*: Total sex ratio.
**:Total mean age.
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time (Table 2, P < 0.05). Virus load was serially quanti-
tated by real-time PCR in the tracked donors. As shown
in Table 3, the number of virus copies increased in all
the donors. Once again, 1b genotype virus RNA was
higher in the follow up period (P < 0.05). Altogether,
these data suggested that 1b genotype infection led to
more serious liver function impairment for local donors.
Discussion
Since blood transfusion was generally accepted as one of
the main dissemination pathways, more and more rigour
test procedure was employed to detect HCV in donors
[18]. In the current study, HCV average infection rate
(0.45%) in local donors was much lower than that of
Chinese open population. One of the reasons might be
the strict questionnaire before donation and a great
Figure 3 Genotype distribution and switch in donors and patients. Blood sample form 200 represented donors and 100 patients were
genotyped. Then genotype 1b and 2a cases were counted. After that, rate of 1b and 2a cases were distributed in different years. A, genotype
1b and 2a comparison in donors (blank) and patients (black); B, genotype 1b distribution from the year of 2000 to 2009; C genotype 2a
distribution from the year of 2000 to 2009.
Table 2 ALT levels in the consecutive test of represented
anti-HCV reactive donors
Donor Number Genotype Age Sex ALT (U.L
-1)
6 12 18 24 (month)
NO.17 3a 48 F 30 41 48 57
NO.26 1b 27 F 48 66 80 118 *
NO.28 1b 41 M 34 59 110 157 *
NO.43 2a 30 F 45 56 ND 105
NO.59 1a 41 M 48 59 77 119
NO.70 2b 50 M 55 62 90 115
NO.74 2a 35 M 38 ND 71 93
NO.77 1b 38 M 54 79 93 147 *
NO.93 NC 24 F 55 57 66 ND
NO.96 1b 39 F 44 49 73 127 *
ND: not determined.*:P < 0.05 when compared to other genotypes.
Table 3 HCV load in the following test of represented
antibody reactive donors
Viral load (copies/ml)
Donor
Number
Genotype Age Sex 6 12 18 24 (month)
NO.17 3a 48 F 3.1E1 2.9E2 3.5E2 1.2E3
NO.26 1b 27 F 4.2E2 3.9E2 2.5E3 1.6E4 *
NO.28 1b 41 M 4.5E1 4.9E2 6.5E3 2.5E4 *
NO.43 2a 30 F 3.7E2 5.9E2 ND 1.5E4
NO.59 1a 41 M 4.4E2 3.8E2 3.5E3 1.9E4
NO.70 2b 50 M 5.2E2 5.9E2 8.0E3 NC
NO.74 2a 35 M 3.2E1 ND 4.0E3 7.4E3
NO.77 1b 38 M 3.2E2 4.9E3 9.0E3 2.4E4 *
NO.93 NC 24 F 3.1E1 2.9E2 3.5E2 ND
NO.96 1b 39 F 2.2E2 3.9E2 6.5E3 1.8E4 *
ND: not determined. *:P < 0.05 when compared to other genotypes.
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the questionnaire could not deny the possibility of low-
grade infection, thus the value of S/CO and virus RNA
in most anti-HCV reactive donors in the present study
were not so high.
The infection rate decreased from the year of 2004, in
which gold-fast strip test was used before blood collec-
tion in our blood bank. Actually, without gold-fast strip
test, the infection rate was much close to Sosa-Jurado et
al reports (0.81% v.s. 0.84%). Interestingly, they observed
descending HCV infection rate also from the year of
2003 to 2006 and contributed this decrease to stringent
questionnaire [11].
Genotyping of HCV is necessary for clinic treatment
and care counseling [19,20]. It is also useful to monitor
the virus strains distribution profile and identify risk fac-
tors involved with transmission [11,21]. Blood transfu-
sion was one of the main dissemination pathways. Thus
it is great significant to analyze HCV genotype distribu-
tion for the sake of infection control. Although bulks of
data described HCV genotype distribution in donors
from different region [7,8,11,16], the situation in differ-
ent region of China is somewhat unknown. Thus
according to our knowledge, the present study firstly
displayed the HCV genotype distribution in local region.
Althougth NS5b region sequences is thought as the
most reliable technique fors u b t y p i n g ,h i t h e r t o5 ’ non
coding region of HCV was the one of the most con-
served sequence and thus extensively adapted in sub-
type discrimination, especially in clinic HCV investiga-
tion. Other HCV gene fragments can also be used for
genotyping. But they are not so popular because of
more possible mutation, uncertain PCR products, less
convenience and much higher costs in clinic. Before bet-
ter and mature genotyping strategy innovation, 5’ non
coding region of HCV is the feasible choice for clinic
investigation.
As occurred in other Eastern Asia region, 1b and 2a
subtype prevailed in local region although other sub-
types were observed also [16,17,22]. What’sm o r e ,w e
found that the main prevailed subtypes in patients and
donors were no difference. Interestingly, 1b and 2a sub-
type in local HCV infected donors underwent a switch.
Donors infected with 1b virus descended in the past
years, while donors infected with 1b virus climbed. It is
not clear yet why this switch happened. One of the pos-
sible machinery is the population mobility. In fact 1b
virus infection was prevailed in the south region of
China and 2a virus infection was prevailed in the north
region of China [23]. Since local city is at the cross of
south and north, the observed subtype switch was no
strange.
To track the donor’s HCV infection, we made a two-
years follow up in some anti-HCV reactive donors.
Bulks of evidence showed that 1b genotype could bring
more serious damage to liver [24]. Since we have ruled
out other hepatitis virus infection, our data was consis-
tent with that postulation according to the ALT level in
the followed time. Again, viral load measurement also
confirmed that 1b HCV virus duplicated more quickly
than other genotypes did, which contributed to the liver
function damage [25].
Conclusion
The current study provided data of HCV infection in
China blood donors during the past ten years. The
infection rate in local donors was lower than general
population and descended in recent years. Genotypes
were clarified in the represented donor sample pool and
1b subtype was the prevailed strains. But 1b and 2a gen-
otype switched in the past years in local region. These
results threw more light on HCV infection of blood
donors in China, at least in the Northern region.
Materials and methods
Blood donor, sample collection and follow up
Volunteer blood donors from both urban and rural
areas in Xi’an City, from January of 2000 to December
of 2009, were recruited into current study. They were
medically assessed and denied any known risk factors
for viral infection listed in the questionnaire. 200 donors
with HCV (20 donors each year), ruled out HBV infec-
tion, were asked to give peripheral blood samples for
genotyping. The serum were isolated from the samples,
then subpackaged and stored at -80°C before analysis.
Ten samples from the chosen 200 donors (donated
before the December of 2007 and negative for other
hepatitis virus) were followed up in the next 2 years.
The sampling, isolation and storage procedures were
just like the mentioned above. The present study was
approved by the Ethics Committee of Fourth Military
Medical University and the informed consents were
signed.
ELISA for anti-HCV detection
Test of the anti-HCV antibody were performed by
ELISA using automatic enzyme detection system (Tecan
GroupLtd., Mannedorf, Switzerland) and commercial kit
(InTec Products, Xiamen, China). Briefly, 96-well plates
were coated with antigen. Donors’ peripheral blood
serum was isolated and added into wells by automatic
enzyme detection system before incubation. The plates
were subsequently washed 5 times with PBST, and then
the horseradish peroxidase labeled mono-antibody was
added. After incubation, followed the manufacturer’s
instructions, washed plates and developed colorant to
determine the results with absorbance reader (Thermo
Scientific, Wohlen, Switzerland).
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To measure the ALT level, donors’ peripheral blood
serum was isolated and employed to automatic bio-
chemistry analyzer (Hitachi, Tokyo, Japan) with com-
mercial Kit (Fousun Long March Medical Ltd.,
Shanghai, China).
Nucleic acid assay of HCV viral load
RNA from donor’s blood sample was prepared accord-
ing to the manufacturers’ manual (Qiagen, Hilden, Ger-
many). In brief, 500 μl isolated serum was mixed with
500 μl TRIzol regent and extracted with chloroform and
alcohol. After quantitation, reverse transcribed into
cDNA using random primers was performed (Qiagen,
Hilden Germany). After that, real time PCR was used to
detect HCV RNA according the manufacture’sm a n u a l
(Daan Gene, Shenzhen, China) with standard controls
[3,26]. Briefly, extracted RNA was measured with fluor-
escence labeled and self-quench probe and Perkin Elme
PCR analyzer (PTC-200, Perkin Elmer, Covina, USA).
The viral load used the copies/ml as the units.
Genotyping
Genotyping was accomplished according to reported
methods [7,8,27]. Briefly, Extracted RNA from the
peripheral blood of 200 donors or 100 confirmed
patients. Then the reverse transcription with random
hexaprimers was carried out. After that, the seminested
PCR of the 5’ non-coding region with generic primers
were performed. Amplicons were digested by restriction
enzymes (Takara, Osaka, Japan). The digestion model,
possible products and genotype categorization were
schemed in Fig. 4.
Statistical analysis
Differences between groups were statistically analyzed
using SPSS 10.0.When P < 0.05, the difference was con-
sidered significant.
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